organism: Homo sapiens
attributes.tag: gap_accession
attributes.value: phs003452
attributes.tag: submitter handle
attributes.value: NCI_Pembrolizumab_MIBC
attributes.tag: biospecimen repository
attributes.value: NCI_Pembrolizumab_MIBC
attributes.tag: study name
attributes.value: Phase 2 Study of Pembrolizumab in Combination with Gemcitabine and Cisplatin as Neoadjuvant Therapy
attributes.tag: study design
attributes.value: Case Set
attributes.tag: biospecimen repository sample id
attributes.value: patient_116_CD3_C1_RNA-Seq
attributes.tag: submitted sample id
attributes.value: patient_116_CD3_C1_RNA-Seq
attributes.tag: submitted subject id
attributes.value: patient_116
attributes.tag: gap_sample_id
attributes.value: 5699520
attributes.tag: gap_subject_id
attributes.value: 4644995
attributes.tag: sex
attributes.value: male
attributes.tag: study disease
attributes.value: Urinary Bladder Neoplasms
attributes.tag: body site
attributes.value: CD3-positive PBMC
attributes.tag: is tumor
attributes.value: No
attributes.tag: subject is affected
attributes.value: Yes
attributes.tag: gap_consent_code
attributes.value: 1
attributes.tag: gap_consent_short_name
attributes.value: DS-CA